Luciano Izzo1, Daniela Messineo2, Pierfrancesco DI Cello3, Virgilio Nicolanti4, Antonio Sterpetti4, Sara Izzo5, Paolo Izzo4. 1. Pietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; luciano.izzo@uniroma1.it. 2. Department of Radiological Sciences, Oncology and Pathology, Sapienza University, Rome, Italy. 3. UOC Chirurgia Generale Frosinone-Alatri presso ASL Frosinone, Frosinone, Italy. 4. Pietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. 5. Multidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Luigi Vanvitelli University of Campania, Naples, Italy.
Abstract
BACKGROUND: The aim of the present work was to evaluate the prognostic significance in patients with T1 breast cancer of tissue expression of the two oncosuppressors phosphatase and tensin homolog (PTEN) and non-metastatic clone 23 (NM23) as detected by immunohistochemistry. MATERIALS AND METHODS: We prospectively analyzed 62 patients who underwent surgery for a T1 stage breast cancer. Expression of PTEN and NM23 was tested for correlation with clinical characteristics and clinical outcome. RESULTS: Of the 62 patients considered for our study, 16 underwent mastectomy and 46 underwent conservative surgical treatment. The surgery was considered radical (R0) in all cases described. PTEN and NM23 expression was higher in patients with no lymph node metastases and no recurrent cancer at a mean follow-up of 36 months (range=6-48 months). This correlation was more evident when both PTNE and NM23 expression were highly expressed (p<0.0001). CONCLUSION: Low or lack of PTEN and NM23 immunohistochemical expression in cancer tissue is a risk factor for lymph node involvement and recurrent disease. It may represent a valid prognostic factor in planning therapy in patients who had surgery for T1 breast cancer. Copyright
BACKGROUND: The aim of the present work was to evaluate the prognostic significance in patients with T1 breast cancer of tissue expression of the two oncosuppressors phosphatase and tensin homolog (PTEN) and non-metastatic clone 23 (NM23) as detected by immunohistochemistry. MATERIALS AND METHODS: We prospectively analyzed 62 patients who underwent surgery for a T1 stage breast cancer. Expression of PTEN and NM23 was tested for correlation with clinical characteristics and clinical outcome. RESULTS: Of the 62 patients considered for our study, 16 underwent mastectomy and 46 underwent conservative surgical treatment. The surgery was considered radical (R0) in all cases described. PTEN and NM23 expression was higher in patients with no lymph node metastases and no recurrent cancer at a mean follow-up of 36 months (range=6-48 months). This correlation was more evident when both PTNE and NM23 expression were highly expressed (p<0.0001). CONCLUSION: Low or lack of PTEN and NM23 immunohistochemical expression in cancer tissue is a risk factor for lymph node involvement and recurrent disease. It may represent a valid prognostic factor in planning therapy in patients who had surgery for T1 breast cancer. Copyright
Authors: E Razis; M Bobos; V Kotoula; A G Eleftheraki; H P Kalofonos; K Pavlakis; P Papakostas; G Aravantinos; G Rigakos; I Efstratiou; K Petraki; D Bafaloukos; I Kostopoulos; D Pectasides; K T Kalogeras; D Skarlos; G Fountzilas Journal: Breast Cancer Res Treat Date: 2011-05-19 Impact factor: 4.872
Authors: Elena López-Knowles; Sandra A O'Toole; Catriona M McNeil; Ewan K A Millar; Min R Qiu; Paul Crea; Roger J Daly; Elizabeth A Musgrove; Robert L Sutherland Journal: Int J Cancer Date: 2010-03-01 Impact factor: 7.396
Authors: C Charpin; S Garcia; P Bonnier; F Martini; L Andrac; N Horschowski; M N Lavaut; C Allasia Journal: J Pathol Date: 1998-04 Impact factor: 7.996